Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, July 21, 2026, 11:00-11:30 AM CT
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2026—When new biomarkers become part of clinical practice, the fundamental question—Will this work?—soon gives way to an equally important group of interrogatives: who, what, when, where, why, and how. At Michigan Medicine, introducing two biomarkers—glial fibrillary acidic protein, or GFAP, and ubiquitin C-terminal hydrolase L1, or UCH-L1—into the emergency department to evaluate traumatic brain injury emphasized the how of the matter.
January 2026—For Jansen Seheult, MD, and others deeply committed to bringing artificial intelligence to the laboratory, it’s impossible to deny that algorithm development has advanced by leaps and bounds. Take Mayo Clinic in Rochester, where Dr. Seheult is medical director of digital pathology and artificial intelligence in hematopathology. More than 20 artificial intelligence algorithms are deployed across the clinical practice in pathology and laboratory medicine. Yet that’s a small fraction of all the algorithms that have been developed at the clinic.
January 2026—Translating cytokine science into better cancer care was the focus of a presentation at last year’s ADLM meeting, where the toxicities associated with CAR T-cell therapy were explained with cases and the need to measure cytokines was made clear.
January 2025—In the 2025 edition of the CAP accreditation checklists are new requirements on humidity, specimen self-collection, body fluid crystal analysis, and pneumatic tube transport of blood specimens for platelet aggregation or other platelet function testing. The new checklist edition was released last year on Dec. 9.
January 2026—Based on the results of Destiny-PanTumor02,1 targeted HER2-based therapies are now available as treatment options agnostic of tumor type. As oncologists seek to offer these targeted therapies to the patients likely to benefit, many laboratories have had to determine how best to expand the use of existing HER2 assays. At the same time, other laboratories may now see testing volumes increasing to justify new validation.
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
January 2025—A retired pathologist believes pathologists should be more involved in gross examination of specimens, not just microscopic analysis. A pathologist praises the Canadian series “Coroner” for its realistic portrayal of the forensic pathology world, crediting the involvement of a real forensic pathologist as a consultant.
January 2026—The CAP president emphasizes the importance of inspiring others in the field of pathology. This can be achieved by encouraging new voices to join the field, engaging with medical students, and actively participating in the CAP.
January 2026—Federally qualified health centers (FQHCs) in Illinois demonstrated higher guideline adherence for kidney disease testing compared to non-FQHCs. Patients with low eGFR or diabetes at FQHCs were more likely to receive recommended uACR and dual testing, respectively.
January 2026—Ossifying fibromyxoid tumors with lipomatous and cartilaginous differentiation are rare mesenchymal neoplasms that can be challenging to diagnose. A study identified six cases with these features, expanding the tumor’s known histomorphological spectrum.
